

# PRIOR AUTHORIZATION REQUEST

### <u>Eohilia</u>

Patient In	formation:				
Name:					-
Member I	D:				-
Address:					_
City, State	e 7in·				_
Date of B	•				_
	er Information:				_
Name:					_
NPI:					_
Phone Nu	ımber:				_
Fax Num	ber				_
Address:					-
City, State	e. Zip:				-
	ed Medication				_
Rx Name					_
Rx Streng	ath				_
Rx Quant					_
Rx Frequ	•				_
Rx Route	•				_
Administration:					
Diagnosis	and ICD Code:				_
prescribed a quantities c Upon recei SECTIO requests medicati	a medication for your an be provided. Plea pt of the completed NA: Please not Pharmacy prions that are not	efit requires that we review certain requests for coverage with the proposition patient that requires Prior Authorization before benefit coverage or coverage complete the following questions then fax this form to the toll-free not form, prescription benefit coverage will be determined based or the that supporting clinical documentation is required or authorization reviews can be subject to trial with a listed within the criteria. The policies are subject to the trial with a listed within the criteria. The policies are subject to the trial with a listed within the criteria. The policies are subject to the trial with a listed within the criteria.	verage of umber lis the pla for <b>AL</b> addition chance	f additiona sted below an's rules <u>L PA</u> nal ge base	il 7. 5.
	What is the diagnos [] Eosinophilic esop	sis or indication? hagitis (If checked, go to 2)			
	[] Other (If checked	, no further questions)			
	Is the patient greate [If no, no further qu	er than or equal to 11 year(s) of age? estions.]	Yes	No	
3	Is the requested me	edication being prescribed by or in consultation with an allergist	Yes	No	

If you have any questions, call: 1-888-258-8250

Version 07.2025

# **PRIOR AUTHORIZATION REQUEST**

	or gastroenterologist? [If no, no further questions.]			
4	Does the patient have a diagnosis of eosinophilic esophagitis as confirmed by an endoscopic biopsy demonstrating greater than or equal to 15 intraepithelial eosinophils per high-power field? [If no, no further questions.]	Yes	No	
5	Does the patient have dysphagia on at least 4 days in any 2 consecutive weeks measured by the Dysphagia Symptom Questionnaire (DSQ)? [If no, no further questions.]	Yes	No	
6	Has documentation been provided to confirm that the patient has a trial and failure with a proton pump inhibitor (received at least 8 weeks of therapy at maximal doses) or has a documented intolerance or contraindication? Examples of proton pump inhibitors are omeprazole, esomeprazole, pantoprazole, etc. ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No	
7	Has the patient tried dietary modifications to manage eosinophilic esophagitis? [NOTE: Examples of dietary modifications to treat eosinophilic esophagitis include an elemental diet or an elimination diet.] [If yes, skip to question 9.]	Yes	No	
8	Has the provider determined that the patient is not an appropriate candidate for dietary modifications? [If no, no further questions.]	Yes	No	
9	Does the provider attest that the patient will be monitored for infection? [If no, no further questions.]	Yes	No	
10	Will the requested medication be used concurrently with Dupixent (dupilumab)? [If yes, no further questions.]	Yes	No	
11	Is the patient currently receiving the requested medication? [If yes, skip to question 13.]	Yes	No	
12	Has the patient been treated previously with a 12-week course of the requested medication? [No further questions.]	Yes	No	
13	Has documentation been provided to confirm that the patient is currently receiving a course of the requested medication and additional medication is needed to complete a 12-week course of treatment? If yes, please list how many weeks of the current course the patient has received of the requested medication:  ACTION REQUIRED: Submit supporting	Yes	No	
	documentation. [NOTE: The maximum recommended treatment is for 12 weeks. For a patient who			
If you have any				

If you have any questions, call: 1-888-258-8250



#### PRIOR AUTHORIZATION REQUEST

has started therapy but has not completed 12 weeks, the approval end date should be the number of weeks remaining to allow a total of 12 weeks of treatment.]

Please document the diagnoses, symptom	ns, and/or any other information important to this review:
SECTION B: Physician Signature	

PHYSICIAN SIGNATURE

DATE

#### **FAX COMPLETED FORM TO: 1-833-896-0656**

**Disclaimer:** An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

**Confidentiality:** The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.

If you have any questions, call: 1-888-258-8250

Version 07.2025